Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Frank J Calzone

Showing results (1-10 of 9) with videos related to

Pageof 1
Sort By:
The Journal of Pharmacology and Experimental Therapeutics|March 10, 2011
Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma modelsPedro J Beltran, Young-Ah Chung, Gordon Moody, et al.
The Journal of Endocrinology|February 5, 2014
IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in miceGordon Moody, Pedro J Beltran, Petia Mitchell, et al.
Plos One|February 6, 2013
Epitope-specific mechanisms of IGF1R inhibition by ganitumabFrank J Calzone, Elaina Cajulis, Young-Ah Chung, et al.
Breast Cancer Research : BCR|February 7, 2006
HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cellsCindy A Wilson, Elaina E Cajulis, Jennifer L Green, et al.
Molecular Carcinogenesis|September 23, 2003
Novel consensus DNA-binding sequence for BRCA1 protein complexesP LouAnn Cable, Cindy A Wilson, Frank J Calzone, et al.
Molecular Cancer Therapeutics|May 8, 2012
Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenograftsRamdev Konijeti, Satomi Koyama, Ashley Gray, et al.
Molecular Cancer Therapeutics|April 16, 2009
AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cellsPedro J Beltran, Petia Mitchell, Young-A Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2014
Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapyPedro J Beltran, Frank J Calzone, Petia Mitchell, et al.
Journal for Immunotherapy of Cancer|December 14, 2023
HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicityDavid Bassan, Leehee Weinberger, Jason Yi, et al.
Pageof 1

Showing results (1-10 of 9) with videos related to

Sort By:
Pageof 1
The Journal of Pharmacology and Experimental Therapeutics|March 10, 2011
Efficacy of ganitumab (AMG 479), alone and in combination with rapamycin, in Ewing's and osteogenic sarcoma modelsPedro J Beltran, Young-Ah Chung, Gordon Moody, et al.
The Journal of Endocrinology|February 5, 2014
IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in miceGordon Moody, Pedro J Beltran, Petia Mitchell, et al.
Plos One|February 6, 2013
Epitope-specific mechanisms of IGF1R inhibition by ganitumabFrank J Calzone, Elaina Cajulis, Young-Ah Chung, et al.
Breast Cancer Research : BCR|February 7, 2006
HER-2 overexpression differentially alters transforming growth factor-beta responses in luminal versus mesenchymal human breast cancer cellsCindy A Wilson, Elaina E Cajulis, Jennifer L Green, et al.
Molecular Carcinogenesis|September 23, 2003
Novel consensus DNA-binding sequence for BRCA1 protein complexesP LouAnn Cable, Cindy A Wilson, Frank J Calzone, et al.
Molecular Cancer Therapeutics|May 8, 2012
Effect of a low-fat diet combined with IGF-1 receptor blockade on 22Rv1 prostate cancer xenograftsRamdev Konijeti, Satomi Koyama, Ashley Gray, et al.
Molecular Cancer Therapeutics|April 16, 2009
AMG 479, a fully human anti-insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cellsPedro J Beltran, Petia Mitchell, Young-A Chung, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 15, 2014
Ganitumab (AMG 479) inhibits IGF-II-dependent ovarian cancer growth and potentiates platinum-based chemotherapyPedro J Beltran, Frank J Calzone, Petia Mitchell, et al.
Journal for Immunotherapy of Cancer|December 14, 2023
HER2 and HLA-A*02 dual CAR-T cells utilize LOH in a NOT logic gate to address on-target off-tumor toxicityDavid Bassan, Leehee Weinberger, Jason Yi, et al.
Pageof 1